Compare Bristol-Myers Squibb Co (BMY) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs National Beverage Corp. — how do they compare? Bristol-Myers Squibb Co trades at $58.72 (market cap $116.30B), while National Beverage Corp. trades at $31.42 (market cap $2.89B). The key difference: Bristol-Myers Squibb Co is far larger — about 40.2× National Beverage Corp.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| BMY | FIZZ | |
|---|---|---|
Market Cap | $116.30B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $47.69 |
52-Week Low | $42.60 | $30.92 |
Enterprise Value | $152.24B | $2.60B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FIZZ (National Beverage Corp.) trades at $31.13, down 7.95% over 24 hours, with a bearish technical signal and recent earnings misses in three of the last four quarters. The company reported $1.2B revenue and $186.82M net income for 2025, with strong profitability margins but a negative net cash flow of $133.21M. A special dividend of $3.25 per share was declared, payable July 30, 2026, providing a near-term catalyst.
Outlook is mixed: strong fundamentals and dividend support value, but technical weakness and earnings misses signal caution. Risks include competitive pressures and consumer spending trends. Analyst consensus is cautious with 50% sell ratings. The stock presents a high-risk opportunity for dividend-focused investors amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
